

# SCIENTIFIC REPORTS

OPEN

## Endocrine cell type sorting and mature architecture in the islets of Langerhans require expression of Roundabout receptors in $\beta$ cells

Melissa T. Adams, Jennifer M. Gilbert, Jesus Hinojosa Paiz, Faith M. Bowman & Barak Blum

Pancreatic islets of Langerhans display characteristic spatial architecture of their endocrine cell types. This architecture is critical for cell-cell communication and coordinated hormone secretion. Islet architecture is disrupted in type-2 diabetes. Moreover, the generation of architecturally correct islets *in vitro* remains a challenge in regenerative approaches to type-1 diabetes. Although the characteristic islet architecture is well documented, the mechanisms controlling its formation remain obscure. Here, we report that correct endocrine cell type sorting and the formation of mature islet architecture require the expression of Roundabout (Robo) receptors in  $\beta$  cells. Mice with whole-body deletion of *Robo1* and conditional deletion of *Robo2* either in all endocrine cells or selectively in  $\beta$  cells show complete loss of endocrine cell type sorting, highlighting the importance of  $\beta$  cells as the primary organizer of islet architecture. Conditional deletion of *Robo* in mature  $\beta$  cells subsequent to islet formation results in a similar phenotype. Finally, we provide evidence to suggest that the loss of islet architecture in *Robo KO* mice is not due to  $\beta$  cell transdifferentiation, cell death or loss of  $\beta$  cell differentiation or maturation.

The islets of Langerhans display typical, species-specific architecture, with distinct spatial organization of their various endocrine cell types<sup>1–5</sup>. In the mouse, the core of the islet is composed mostly of insulin-secreting  $\beta$  cells, while glucagon-secreting  $\alpha$  cells, somatostatin-secreting  $\delta$  cells and pancreatic polypeptide-secreting PP cells are located at the islet periphery<sup>3</sup>. In humans and other primates, islet architecture is more complex, but still conforms to the overall structure of several  $\beta$  cell lobules surrounded by mantles of  $\alpha$ ,  $\delta$  and other endocrine cells types<sup>4,5</sup>. Correct islet architecture facilitates the mature pattern of hormone release, directionality of intra-islet paracrine signaling, and connection with the microvasculature<sup>6,7</sup>. The typical islet architecture is disrupted in obesity, insulin resistance, and diabetes in both humans and rodents<sup>8–14</sup>. Structural islet integrity and architecture are also disrupted in cadaver islets during isolation and culture prior to islet transplantation, as well as after infusion into the portal vein<sup>15–18</sup>. Moreover, the generation of *bona fide* islets of Langerhans from human pluripotent stem cells, in which the three-dimensional islet architecture is recapitulated, remains a pressing challenge in regenerative medicine approaches to diabetes<sup>19,20</sup>.

The formation of the islets of Langerhans in the mouse starts with the delamination of individual pro-endocrine cells from the pancreatic duct, beginning at embryonic day (E) 13.5<sup>21</sup>. These cells then migrate into the mesenchyme, aggregate to form proto-islet clusters, and subsequently rearrange into the typical mantle/core architecture of the mature islets of Langerhans<sup>22</sup>. Interestingly, dissociated rat islets re-aggregate spontaneously in culture, recapitulating the original mantle-core islet architecture, suggesting that the signals and forces controlling islet architecture are islet-autonomous<sup>23</sup>. Despite the four decades that have passed since the typical islet architecture was first described<sup>24,25</sup>, the mechanisms controlling the formation of mature islet architecture during development and its maintenance in the adult remain largely unresolved<sup>22,26</sup>.

Roundabout (Robo) receptors are cell surface receptors that bind the ligand Slit, originally recognized for their involvement in axon guidance and neuronal migration<sup>27</sup>. Among the four Robo family members, Robo1 and Robo2 were shown to be expressed in the islets of Langerhans of both humans and rodents<sup>28–33</sup>. Furthermore, *in vitro* analyses illustrate that Slit-Robo signaling in the islet can improve  $\beta$  cell survival during stress and

Department of Cell and Regenerative Biology, University of Wisconsin-Madison School of Medicine and Public Health, 1111 Highland Ave., Madison, WI, 53705, USA. Correspondence and requests for materials should be addressed to B.B. (email: [bblum4@wisc.edu](mailto:bblum4@wisc.edu))

hyperglycemia and to potentiate insulin secretion<sup>33</sup>. However, the role of this pathway in the islet *in vivo* has not yet been demonstrated.

It recently was shown that a double deletion of *Robo1* and *Robo2* in lung pulmonary neuroendocrine cells (PNECs) results in the loss of PNECs' clustered architecture<sup>34</sup>. The delamination, migration and aggregation of the islets of Langerhans involve several Robo-related neuronal proteins such as Semaphorin, Ephrin/Eph and N-CAM<sup>35–40</sup>, as well as direct signals from the nervous system<sup>41</sup>. Moreover, Robo receptors themselves have been implicated in collective cell movement during organogenesis in various mammalian tissues<sup>42,43</sup>. We thus hypothesized that beyond their role in insulin secretion and  $\beta$  cell survival, Robo receptors may also be involved in the organogenesis of the islets of Langerhans, similar to their role in PNECs in the lung.

Here, we show that expression of Robo receptors in  $\beta$  cells is required for endocrine cell type sorting and mature islet architecture. Mice lacking *Robo1* and *Robo2* in all endocrine cells or selectively in  $\beta$  cells show complete loss of endocrine cell type sorting in the islets. Moreover, deletion of Robo receptors in mature  $\beta$  cells after islet formation has been completed also results in intermixing of endocrine cell types and loss of islet architecture. Finally, lineage-tracing experiments in  $\beta$  cell-selective *Robo* knockouts (*Robo* KO) provide evidence suggesting that disruption of islet architecture in *Robo* KO mice is not due to transdifferentiation,  $\beta$  cell death, or insufficient  $\beta$  cell differentiation or maturation.

## Results

### Robo receptors are required for endocrine cell type sorting and mature architecture of the islets of Langerhans.


Current understanding of the formation of the mature architecture of the islets of Langerhans during development suggests that, beginning at E13.5, individual endocrine progenitors within the pancreatic duct independently turn on the transcription factor Neurogenin3 (Neurog3), and delaminate from the duct into the surrounding mesenchyme as single cells. These delaminated cells then migrate away from the duct and coalesce to form the mature islet architecture<sup>35,37,44,45</sup>. To test our hypothesis that Robo receptors are involved in the organogenesis of the islets of Langerhans, we generated an early endocrine progenitor knockout of *Robo* by crossing *Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice<sup>34</sup> with *Neurog3-Cre* mice<sup>46</sup>. *Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice harbor a linked *Robo1* deletion allele (*Robo1* $\Delta$ ) and conditional *Robo2* deletion allele (*Robo2<sup>flx</sup>*). Neurog3 is expressed in all endocrine progenitors during their delamination from the duct, and its expression is subsequently turned off prior to endocrine cell aggregation to form proto-islet clusters<sup>47,48</sup>. The resulting *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice carry a whole-body deletion of *Robo1*, and a pancreatic endocrine-selective deletion of *Robo2*. This strategy was chosen to eliminate redundant Robo signaling and to avoid the homozygous lethality of *Robo2* whole-body deletion<sup>49</sup>. *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* progeny are viable and appear normal.

Upon histological analysis of pancreata from adult (2 months old) *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice we found that proto-islets do form in the absence of Robo signaling in endocrine cells (Fig. 1A), suggesting that Robo is not required for endocrine cell aggregation. Strikingly, most *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* islets are long, thin, disorganized, and lie directly along the duct (Fig. 1A, lower right panel). Consistent with their lengthy appearance, the Circularity Index of *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* islets is significantly decreased compared to controls (Circularity Index =  $0.43 \pm 0.02$  for controls and  $0.33 \pm 0.02$  for *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>*,  $P = 0.0015$ ,  $n = 10$ –20 islets each for two independent mice in each genotype) (Fig. 1B). Moreover, both  $\alpha$  and  $\delta$  cells in islets of *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice lose their stereotypical location in the islet periphery (the two outermost layers of cells in the islet), and instead are intermingled with  $\beta$  cells throughout the islet. Thus, while in control mice, 84% and 81% of  $\alpha$  and  $\delta$  cells, respectively, are located in the islet periphery, only 39% and 54% of  $\alpha$  and  $\delta$  cells, respectively, are located in the islet periphery in islets of *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice ( $P < 0.0001$ ,  $n = 10$ –20 islets each for two independent mice in each genotype) (Fig. 1C, Supplemental Fig. 2A,B). The overall islet size, on the other hand, was similar between *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* and controls ( $15918 \mu\text{m}^2$  and  $16058 \mu\text{m}^2$ , respectively) (Fig. 1D). Furthermore, there was no significant difference in  $\alpha$  cells as a percentage of total islet cells between control and *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice (Fig. 1E). Islets of control *Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* and *Robo1* $^{+/+}$ ,*2<sup>flx/flx</sup>* mice without the *Cre* transgene show normal islet architecture, indicating that loss of *Robo1* alone is not sufficient for the observed disruption of islet architecture (Supplemental Fig. 1).

### Deletion of Robo receptors in $\beta$ cells alone is sufficient to disrupt endocrine cell type sorting and islet architecture.

Because deletion of Robo receptors in *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice results in disruption of islet architecture, without apparent interference with endocrine cell aggregation into proto-islet clusters, we hypothesized that the deletion of *Robo* may affect later events in islet organogenesis. To test this hypothesis, we generated a  $\beta$  cell-selective deletion of *Robo* by crossing *Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice with an *Insulin-Cre* line (*Ins2-Cre*)<sup>50</sup>.


As in the case of *Neurog3-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>*, islets of Langerhans from *Ins2-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice show marked defects in islet architecture and endocrine cell type sorting compared to islets from control littermates (Fig. 2A). Islets of *Ins2-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* are thus less circular than controls (Circularity Index =  $0.37 \pm 0.02$ , and  $0.45 \pm 0.02$  for *Ins2-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* and controls, respectively,  $P = 0.0005$ ,  $n = 10$ –20 islets each for three independent mice in each genotype) (Fig. 2B). Likewise, while in control mice, 78% and 83% of  $\alpha$  and  $\delta$  cells, respectively, are located in the islet periphery, only 36% and 46% of  $\alpha$  and  $\delta$  cells, respectively, are located in the islet periphery in islets of *Ins2-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice ( $P < 0.0001$ ,  $n = 10$ –20 islets each for three independent mice in each genotype) (Fig. 2C, Supplemental Fig. 3A,B). The overall islet size was significantly different between *Ins2-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* and controls ( $15695 \mu\text{m}^2$  and  $20959 \mu\text{m}^2$ , respectively,  $P = 0.05$ ,  $n = 10$ –20 islets each for three independent mice in each genotype) (Fig. 2D). No significant difference in  $\alpha$  cells over total islet cells between control and *Ins2-Cre;Robo1* $\Delta/\Delta$ ,*2<sup>flx/flx</sup>* mice was observed (Fig. 2E).



**Figure 1.** Robo receptors are required for endocrine cell type sorting and mature architecture of the islets of Langerhans. (A) Immunofluorescence staining for  $\beta$  cells (Insulin, red) and  $\alpha$  cells (glucagon, green) of control ( $Robo1^{+/Δ}, 2^{+/flx}$  and  $Neurog3-Cre;Robo1^{+/+}, 2^{+/+}$ ) and  $Neurog3-Cre;Robo1^{Δ/Δ}, 2^{flx/flx}$  islets from 2 month old mice. (B) Average Circularity Index of control ( $Robo1^{+/Δ}, 2^{+/flx}$  and  $Neurog3-Cre;Robo1^{+/+}, 2^{+/+}$ ) and  $Neurog3-Cre;Robo1^{Δ/Δ}, 2^{flx/flx}$  islets. (C) Percentage of total  $\alpha$  cells found in periphery of the islet in control ( $Robo1^{+/Δ}, 2^{+/flx}$  and  $Neurog3-Cre;Robo1^{+/+}, 2^{+/+}$ ) vs.  $Neurog3-Cre;Robo1^{Δ/Δ}, 2^{flx/flx}$  mice. (D) Average size of control ( $Robo1^{+/Δ}, 2^{+/flx}$  and  $Neurog3-Cre;Robo1^{+/+}, 2^{+/+}$ ) and  $Neurog3-Cre;Robo1^{Δ/Δ}, 2^{flx/flx}$ . (E) Percent of  $\alpha$  cells out of total cells in control ( $Robo1^{+/Δ}, 2^{+/flx}$  and  $Neurog3-Cre;Robo1^{+/+}, 2^{+/+}$ ) and  $Neurog3-Cre;Robo1^{Δ/Δ}, 2^{flx/flx}$ .


**Robo receptors are required for endocrine cell type sorting and islet architecture postnatally, and their expression is diminished in obesity.** In some models of type-2 diabetes, islet architecture is distorted, with intermingling of  $\alpha$  and  $\beta$  cells reminiscent of the  $Neurog3-Cre;Robo1^{Δ/Δ}, 2^{flx/flx}$  and  $Ins2-Cre;Robo1^{Δ/Δ}, 2^{flx/flx}$  phenotypes<sup>12</sup>. We therefore wondered whether Robo receptors may be involved in the loss of islet architecture in obesity and diabetes. To test for this possibility, we queried the Genomic Study of Parental Mice database developed by Keller and colleagues<sup>31</sup>, for the expression of *Robo1* and *Robo2*. This database allows searching for gene expression in microarray experiments performed on islets from lean and obese (*Lep<sup>ob/ob</sup>*) mice. We found that both *Robo1* and *Robo2* mRNAs are significantly downregulated in islets from obese mice compared to the lean controls as early as 4 weeks of age (Fig. 3A,B). Further literature search revealed that *ROBO1* and *ROBO2* are similarly downregulated in islets from human type-2 diabetics<sup>28,29</sup>. The diminished expression of Robo receptors in islets from obese, pre-diabetic mice and human type-2 diabetics suggests that these genes may be involved in maintaining islet architecture in the adult.

To further test the hypothesis that Robo receptors are important for islet architecture subsequent to initial islet formation, we generated mice with selective deletion of *Robo* in mature  $\beta$  cells. To this end, we crossed



**Figure 2.** Deletion of Robo receptors in  $\beta$  cells alone is sufficient to disrupt endocrine cell type sorting and islet architecture. (A) Immunofluorescence staining for  $\beta$  cells (Insulin, red) and  $\alpha$  cells (glucagon, green) of control (*Robo1<sup>+/+</sup>,2<sup>+/+</sup>* and *Ins2-Cre;Robo1<sup>+/+</sup>,2<sup>+/+</sup>*) and *Ins2-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  islets from 2 month old mice. (B) Average Circularity Index of control (*Robo1<sup>+/+</sup>,2<sup>+/+</sup>* and *Ins2-Cre;Robo1<sup>+/+</sup>,2<sup>+/+</sup>*) and *Ins2-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  islets. (C) Percentage of total  $\alpha$  cells found in periphery in control (*Robo1<sup>+/+</sup>,2<sup>+/+</sup>* and *Ins2-Cre;Robo1<sup>+/+</sup>,2<sup>+/+</sup>*) vs. *Ins2-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  islets. (D) Average size of control (*Robo1<sup>+/+</sup>,2<sup>+/+</sup>* and *Ins2-Cre;Robo1<sup>+/+</sup>,2<sup>+/+</sup>*) and *Ins2-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  islets. (E) Percent of  $\alpha$  cells out of total cells in control (*Robo1<sup>+/+</sup>,2<sup>+/+</sup>* and *Ins2-Cre;Robo1<sup>+/+</sup>,2<sup>+/+</sup>*) and *Ins2-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$* .


*Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  mice with *Urocortin3 (Ucn3)-Cre* mice<sup>52</sup>. Ucn3 is a  $\beta$  cell-selective maturation marker in mice that is highly expressed in  $\beta$  cells starting around postnatal day 10 (P10), subsequent to islet organogenesis<sup>19,53</sup>. Thus, in  $\beta$  cells from *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  mice, deletion of Robo will occur only after islet architecture has been established. We hypothesized that if Robo signaling is required for islet architecture subsequent to initial islet formation, then the islets in *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  mice will have a similar architectural phenotype as those of the *Neurog3-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  and *Ins2-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  models. However, if Robo receptors are only needed for the initial establishment of islet architecture, then islet architecture in *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  mice will not differ from that of the controls. We found that the average circularity index of *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  was significantly lower than controls (Circularity Index =  $0.41 \pm 0.02$ , and  $0.47 \pm 0.02$  for *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  and controls, respectively,  $P = 0.0164$ ,  $n = 10-20$  islets each for four independent mice in each genotype) (Fig. 3D). The islets of *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  mice still show significant intermingling of  $\alpha$  and  $\beta$  cells, similar to that of *Neurog3-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  and *Ins2-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  mice (Fig. 3C). Thus, while in control mice, 85% of  $\alpha$  cells are located in the islet periphery, only 37% of  $\alpha$  cells are located in the islet periphery in islets of *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $flx/flx$*  mice ( $P < 0.0001$ ,  $n = 10-20$  islets each for four independent mice in each



**Figure 3.** Robo receptors maintain endocrine cell type sorting and islet architecture in the adult, and their expression is diminished in obesity. (A,B) Microarray data adapted from Keller and colleagues (Keller *et al.*<sup>51</sup>). Relative expression of *Robo1* (A) and *Robo2* (B) in lean and obese C57BL6 mice at 4 and 10 weeks. Relative expression is defined here as the  $\log_{10}$  of the ratio of (C) Immunofluorescence staining for  $\beta$  cells (Insulin, red) and  $\alpha$  cells (glucagon, green) of control (*Robo1*<sup>+/+</sup>,2<sup>+/+</sup> and *Ucn3-Cre;Robo1*<sup>+/+</sup>,2<sup>+/+</sup>) and *Ucn3-Cre;Robo1* $\Delta/\Delta$ ,2 $^{flx/flx}$  islets from 2 month old mice. (D) Average Circularity Index of control (*Robo1*<sup>+/+</sup>,2<sup>+/+</sup> and *Ucn3-Cre;Robo1*<sup>+/+</sup>,2<sup>+/+</sup>) and *Ucn3-Cre;Robo1* $\Delta/\Delta$ ,2 $^{flx/flx}$  islets. (E) Percentage of peripheral  $\alpha$  cells in control (*Robo1*<sup>+/+</sup>,2<sup>+/+</sup> and *Ucn3-Cre;Robo1*<sup>+/+</sup>,2<sup>+/+</sup>) vs. *Ucn3-Cre;Robo1* $\Delta/\Delta$ ,2 $^{flx/flx}$  islets. (F) Average size of control (*Robo1*<sup>+/+</sup>,2<sup>+/+</sup> and *Ucn3-Cre;Robo1*<sup>+/+</sup>,2<sup>+/+</sup>) and *Ucn3-Cre;Robo1* $\Delta/\Delta$ ,2 $^{flx/flx}$  islets. (G) Percent of  $\alpha$  cells out of total cells in control (*Robo1*<sup>+/+</sup>,2<sup>+/+</sup> and *Ucn3-Cre;Robo1*<sup>+/+</sup>,2<sup>+/+</sup>) and *Ucn3-Cre;Robo1* $\Delta/\Delta$ ,2 $^{flx/flx}$  islets from 2 month old mice.

genotype) (Fig. 3E).  $\delta$  cells behave the same, but were not quantified (Supplemental Fig. 4). The average islet size of *Ucn3-Cre;Robo1* $\Delta/\Delta$ ,2 $^{flx/flx}$  shows a slight trend towards larger islet than those of controls, but this trend does not reach statistical significance (18157  $\mu$ m<sup>2</sup> and 21968  $\mu$ m<sup>2</sup>, respectively,  $P = 0.1653$ ,  $n = 10$ –20 islets each for four






**Figure 4.** The disrupted islet architecture and increase in  $\alpha$  cell ratio in *Robo*  $m\beta$ KO islets is not due to defects in differentiation or maturation of  $\beta$  cells. **(A)** Immunofluorescent staining for Insulin (red) and Ucn3 (green) of control *Ucn3-Cre;Robo1<sup>+/+</sup>,2<sup>+/+</sup>* and *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2<sup>flx/flx</sup>* islets from 1.5–3 month old mice. **(B)** Immunofluorescent staining for Insulin (red) and MafA (green) of control *Ucn3-Cre;Robo1<sup>+/+</sup>,2<sup>+/+</sup>* and *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2<sup>flx/flx</sup>* islets from 1.5–3 months old mice. Disorganized islets do not show loss of  $\beta$  cell maturation.

independent mice in each genotype) (Fig. 3F). Interestingly, we also observed a significant increase in  $\alpha$  cell ratio in *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2<sup>flx/flx</sup>* islets compared to controls (Fig. 3G).

**The disrupted islet architecture and increase in  $\alpha$  cell ratio in *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2<sup>flx/flx</sup>* islets is not due to  $\beta$  cell death, transdifferentiation or defects in differentiation or maturation.** It has been shown that disrupting endocrine cell differentiation and maturation results in disordered islet architecture, reminiscent of our *Robo* KO phenotype<sup>54–61</sup>. To account for this possibility, we compared expression of the  $\beta$  cell maturation markers MafA and Ucn3 in *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2<sup>flx/flx</sup>* mice and controls by immunofluorescence (Fig. 4A,B). Surprisingly, we observed no change in expression of either MafA or Ucn3 in the  $\beta$  cells in *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2<sup>flx/flx</sup>* islets compared to controls, suggesting that deletion of *Robo* results in loss of islet architecture without apparent loss of  $\beta$  cell differentiation and maturation.



It has previously been reported that reducing Slit-Robo signaling in islets promotes  $\beta$  cell death, while addition of recombinant Slit ligand improves  $\beta$  cell survival under diabetogenic stresses<sup>33</sup>. This suggests that both the intermixed endocrine cell phenotype and the increase in  $\alpha$  cell ratio in *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2<sup>flx/flx</sup>* islets may be caused by  $\beta$  cell death, or replacement of  $\beta$  cells in the islet core by  $\alpha$  cells through developmental reprogramming or transdifferentiation. To test the hypothesis that  $\beta$  cell death contributes to these phenotypes, we performed TUNEL analysis on *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2<sup>flx/flx</sup>* islets both at P13–16, when islets are still expanding, and at 8 weeks of age, when islet formation has been completed. We found no increase in  $\alpha$  or  $\beta$  cell death in either of these stages (Fig. 5A). Analysis of  $\beta$  cell area in *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2<sup>flx/flx</sup>* islets showed a trend towards larger  $\beta$  cell area in the



**Figure 5.** The disrupted islet architecture and increase in  $\alpha$  cell ratio in *Ucn3-Cre;Robo1 $\Delta/\Delta$ 2<sup>flx/flx</sup>* islets is not due to  $\beta$  cell death. (A) TUNEL staining for apoptotic cells (white), counterstained with Insulin (red), and DAPI (blue), showing no cell death in adult and p13 control *Ucn3-Cre;Robo1<sup>+/+</sup>2<sup>+/+</sup>* and *Ucn3-Cre;Robo1 $\Delta/\Delta$ 2<sup>flx/flx</sup>* islets. (B) Percent  $\beta$  cell area of pancreatic sections in control *Ucn3-Cre;Robo1<sup>+/+</sup>2<sup>+/+</sup>* and *Ucn3-Cre;Robo1 $\Delta/\Delta$ 2<sup>flx/flx</sup>* showing a trend towards higher  $\beta$  cell area in *Ucn3-Cre;Robo1 $\Delta/\Delta$ 2<sup>flx/flx</sup>*.

*Robo* KO when compared to controls though this did not reach statistical significance, further pointing against  $\beta$  cell death in *Robo* KO mice as an explanation for the islet architectural defects (Fig. 5B).

To test the hypothesis that  $\beta$  cell transdifferentiation to  $\alpha$  cells is the cause of the observed disrupted islet architecture and increase in  $\alpha$  cell ratio in *Ucn3-Cre;Robo1 $\Delta/\Delta$ 2<sup>flx/flx</sup>* mice, we performed lineage tracing experiments.


**A****B**

**Figure 6.** The disrupted islet architecture and increase in  $\alpha$  cell ratio in *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $^{flx/flx}$*  islets is not due to transdifferentiation of  $\beta$  to  $\alpha$  cells. **(A)** Schematic of constructs used for lineage tracing *Ucn3-Cre* expressing cells. **(B)** Lineage tracing of mature  $\beta$  cells in control *Ucn3-Cre;Robo1 $^{+/+}$ ,2 $^{+/+}$*  and *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $^{flx/flx}$*  islets. Lineage traced  $\beta$  cells express nuclear mCherry (white), and counterstained for Insulin (red), Glucagon (green), and DAPI (blue), showing no transdifferentiation of  $\alpha$  to  $\beta$  cells.

To this end, we crossed *Ins2-Cre;Robo1 $\Delta/\Delta$ ,2 $^{flx/flx}$*  or *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $^{flx/flx}$*  mice with mice carrying a *Rosa26-Lox-Stop-Lox-H2BmCherry* reporter<sup>62</sup> (Fig. 6A). In the resulting progeny, any cell that has ever expressed the *Insulin* promoter in the former or the *Ucn3* promoter in the latter is permanently marked with nuclear histone H2B-mCherry expression. The results obtained using this lineage tracing system showed no significant transdifferentiation of  $\beta$  cells to other cell types in the islet core in either *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $^{flx/flx}$*  mice or *Ins2-Cre;Robo1 $\Delta/\Delta$ ,2 $^{flx/flx}$*  mice (Fig. 6B, Supplemental Fig. 5). We thus concluded that the disrupted islet architecture in *Robo* KO lines and the increase in  $\alpha$  cell ratio seen in the *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $^{flx/flx}$*  mice are likely not caused by defects in  $\beta$  cell differentiation or maturation, accelerated  $\beta$  cell death, or transdifferentiation of  $\beta$  cells to  $\alpha$  cells.

Finally, we examined the glucose regulation of *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $^{flx/flx}$*  mice. Isolation of islets for *in vitro* glucose stimulated insulin secretion (GSIS) is not feasible, because islets of *Robo* KO mice spontaneously dissociate upon isolation, likely due to cell adhesion defects. We thus performed *in vivo* intraperitoneal glucose tolerance tests (IPGTT) on *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $^{flx/flx}$*  mice, compared to control colony-mates at the same age. Male *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $^{flx/flx}$*  mice displayed slight glucose intolerance after overnight fasting. However, female *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2 $^{flx/flx}$*  mice did not show glucose intolerance at the same conditions (Fig. 7).





**Figure 7.** Robo receptors are important for glucose tolerance in male mice. **(A)** Glucose Tolerance Test on male control *Ucn3-Cre;Robo1<sup>+/+</sup>,2<sup>+/+</sup>* and *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2flx/flx* mice fasted overnight showing mild glucose intolerance. **(B)** Glucose Tolerance Test on female control *Ucn3-Cre;Robo1<sup>+/+</sup>,2<sup>+/+</sup>* and *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2flx/flx* mice fasted overnight showing no glucose intolerance.

## Discussion

In this study, we show that Robo receptors are essential for endocrine cell type sorting and mature architecture of the islets of Langerhans in mice. Conditional deletion of *Robo2* in the islets on the background of whole-body deletion of *Robo1* completely abolished the characteristic core-mantle organization of the islets. Instead of sorting to the periphery,  $\alpha$  cells and  $\delta$  cells became intermingled with  $\beta$  cells throughout the islet. The same phenotype was observed upon deletion of *Robo* in all endocrine cells, using a *Neurog3-Cre;Robo1 $\Delta/\Delta$ ,2flx/flx* model and upon selective deletion of *Robo* only in the  $\beta$  cell compartment, using the *Ins2-Cre;Robo1 $\Delta/\Delta$ ,2flx/flx* and *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2flx/flx* models. These results are in agreement with a recent study showing that  $\alpha$  cells are dispensable for morphogenesis of the islets of Langerhans<sup>63</sup>, thus further highlighting the importance of  $\beta$  cells as the primary organizer of islet architecture. It should be noted that none of the three Cre lines used in this study are endocrine-specific. The *Ucn3* promoter is inherently expressed in some cell types in the central nervous system<sup>64</sup>, and the *Neurog3-Cre* and *Ins2-Cre* lines have been shown to have leaky expression in the brain and other neuroendocrine tissues<sup>65,66</sup>. While this can influence behavior and glucose regulation, it is unlikely that leakiness expression of the transgenes in different tissues accounts for the remarkably similar defects in endocrine cell type sorting and islet architecture in all three models.

We further show, using *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2flx/flx* mice, that deletion of *Robo* selectively in mature  $\beta$  cells, after initial islet formation has been completed, also results in loss of endocrine cell type sorting and improper islet architecture. One possible explanation for this observation is that Robo receptors are required for active maintenance of endocrine cell sorting. *Ucn3* is a marker of functionally mature  $\beta$  cells in mice, which starts being expressed in  $\beta$  cells around P10<sup>19,53</sup>. While *Ucn3*-expressing  $\beta$  cells are functionally mature<sup>52</sup>, the islets of P13-P16 mice still undergo proliferative expansion<sup>67</sup>. Thus, a more plausible explanation to the phenotype observed in islets of *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2flx/flx* mice is that postnatal islets require Robo receptors to achieve mature islet architecture and endocrine cell type sorting during the expansion period. Future experiments, namely conditional deletion of *Robo* after weaning<sup>68</sup>, will resolve the question of active *versus* passive control of endocrine cell sorting and islet architecture in the adult. However, it would be interesting to see whether the observed reduction in Robo expression in islets from obese mice and type-2 diabetic humans accounts for the disruption of islet architecture during the islets' compensatory expansion under these conditions.

One notable difference between prenatal and postnatal deletion of *Robo* is the effect on  $\alpha$ -to- $\beta$  cell ratio. While prenatal deletion of *Robo* did not result in a significant difference in  $\alpha$ -to- $\beta$  cell ratio, postnatal *Robo* mutants showed increased  $\alpha$  cell proportions. Our lineage-tracing experiments, as well as the trend towards larger  $\beta$  cell area in the mutant, strongly suggest that the increase in  $\alpha$  cells in the islets of *Ucn3-Cre;Robo1 $\Delta/\Delta$ ,2flx/flx* mice is not the result of  $\beta$  cells transdifferentiating into  $\alpha$  cells. One possible explanation for the difference in  $\alpha$ -to- $\beta$  cell ratio observed between deletion of *Robo* prenatally using *Neurog3-cre* and *Ins2-Cre* and that observed when *Robo* is deleted postnatally with *Ucn3-Cre* is that the former two models delete *Robo* in all  $\beta$  cells, while the latter model only deletes the gene only in mature  $\beta$  cells, thus potentially having a differential influence on the neogenic niche of virgin  $\beta$  cells at the islet periphery<sup>52</sup>.

Defects in endocrine cell type sorting and islet architecture have previously been associated with defects in  $\beta$  cell maturation and/or differentiation<sup>54–61</sup>. Using mature  $\beta$  cell-selective lineage tracing, we found no difference in

the proportion of label-carrying non- $\beta$  cells between islets from *Robo* KO mice and controls, suggesting that deletion of *Robo* does not cause  $\beta$  cells to lose their differentiated identity. This conclusion is supported by the apparently normal expression of the maturation markers MafA and Ucn3 in  $\beta$  cells of *Robo* KO mice. Furthermore, the similar or larger total  $\beta$  cell area in *Robo* KO and control islets, the lack of increase in cell death in *Robo* KO islets, and the similar or larger overall islet size between islets of *Robo* KO models and their respective controls strongly suggest that the defects seen in endocrine cell type sorting and islet architecture are not due to loss of  $\beta$  cells.

*Robo* receptors have been implicated in collective cell movement not only in migrating axons, but also in other mammalian tissues<sup>42,43</sup>. They can function together with their canonical ligands, Slit1-3, or by partnering with other cell surface molecules to regulate cell adhesion and cell motility<sup>27</sup>. Based on results shown here, we propose that the defects in endocrine cell type sorting and islet architecture seen upon deletion of *Robo* in  $\beta$  cells are caused either by the inability of the cells to sense positional cues, the inability of the cells to rearrange their own cytoskeleton in response to positional cues, or the inability of the cells to attach to neighboring cells or to the extracellular matrix to facilitate movement.

Taken together, our data shown here demonstrate that expression of *Robo* receptors in  $\beta$  cells is required for endocrine cell type sorting and mature architecture in the islets of Langerhans. These findings raise the possibility of using *Robo* to prevent and reverse the loss of correct islet architecture in type-2 diabetics, as well as for directing the architecture of islet-like clusters derived by stem cell differentiation to make *bona fide* islets *in vitro* for transplantation into type-1 diabetics.

## Materials and Methods

**Animals.** The experimental protocol for animal usage was reviewed and approved by the University of Wisconsin-Madison Institutional Animal Care and Use Committee (IACUC) under Protocol #M005221, and all animal experiments were conducted in accordance with the University of Wisconsin-Madison IACUC guidelines under the approved protocol. *Robo1*<sup>Δ,2<sup>flx</sup>34</sup>, *Ins2-Cre*<sup>50</sup>, *Neurog3-Cre*<sup>46</sup>, *Urocortin3-Cre*<sup>52</sup> and *Rosa26-Lox-Stop-Lox-H2BmCherry*<sup>62</sup> mice were previously described. All mouse strains were maintained on a mixed genetic background. Control colony mates in all analyses were either *Robo1*<sup>+/Δ,2<sup>+/flx</sup></sup>, *Robo1*<sup>+/+,2<sup>+/+</sup></sup>, or *Robo1*<sup>+/+,2<sup>+/+</sup></sup> with the corresponding *Cre* transgene (see Supplemental Fig. 1). The specificity of *Cre* expression and degree of conditional deletion of *Robo2* are shown in Supplemental Fig. 6.

**Immunofluorescence.** Pancreata were fixed with 4% PFA at room temperature for 1 h, embedded in 30% sucrose and frozen in OCT (Tissue-Tek). Pancreatic sections (10 μm) were stained using a standard protocol. The following primary antibodies and dilutions were used: Guinea Pig anti-Insulin, 1:800, (Dako), Rabbit anti-Glucagon, 1:200, (Cell Signaling), Goat anti-Somatostatin, 1:100, (Santa Cruz), Rabbit anti-Urocortin3, 1:500, (Phoenix) and Rabbit anti-MafA, 1:200, (Cell Signaling). The following secondary antibodies were used: Donkey anti-Guinea Pig 594 (Jackson), Donkey anti-Guinea Pig 647 (Jackson), Donkey anti-Rabbit 488 (Invitrogen), Donkey anti-Rabbit 594 (Invitrogen), Donkey anti-goat 647 (Invitrogen). TUNEL labeling was performed using the CF488A TUNEL Assay Apoptosis Detection Kit (Biotium). Slides were imaged using a Leica SP8 Scanning Confocal microscope or a Zeiss Axio Observer.Z1 microscope.

**Cell counting analysis.** Cells were counted at maximum intensity projected images from 8–10, 10 μm thick confocal z-stacks using the ImageJ cell counter tool. Only cells with visible DAPI stained nuclei were counted. Cells were considered to be in the islet mantle if they fell within the 2 outermost cell layers of the islet, or core if they fell within any layers deeper than the outermost 2 cell layers. Only islets with at least 40 cells, with 10 or more cells being non  $\beta$  cells were counted for determining core/mantle localization.

**Islet size and shape analysis.** Islet size and shape analyses were performed on the same images used for cell counting. All non-islet nuclei were erased using the ImageJ outline and clear outside functions. The subsequent images were then converted to 8 bit and set as threshold. Islet size and shape was determined using the Analyze Particles macro of ImageJ, which gives both a readout of area in μm<sup>2</sup>, and a Circularity Index that is calculated using the formula  $\text{circularity} = 4\pi(\text{area}/\text{perimeter}^2)$ .  $\beta$  cell area analysis was performed on four whole pancreas sections per mouse, that were at least 100 μm apart. Whole sections were stained for insulin and DAPI, and then imaged as 10x tile scans on a Leica SP8 Scanning Confocal microscope. Using ImageJ, each channel was converted to threshold, background was erased, and the area was measured using the Analyze Particles function. To obtain the  $\beta$  cell area per section, the insulin area was divided by the DAPI area for each section and converted to a percentage.

**Statistical analysis.** Data are presented as average ± SEM unless otherwise indicated. All *P* values were calculated using a Student's *t*-test using Prism 7 Graph Pad. *P* values of less than 0.05 were considered significant.

**Data availability.** All data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

## References

1. Cabrera, O. *et al.* The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. *Proc Natl Acad Sci USA* **103**, 2334–9 (2006).
2. Brissova, M. *et al.* Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. *J Histochem Cytochem* **53**, 1087–97 (2005).
3. Kim, A. *et al.* Islet architecture: A comparative study. *Islets* **1**, 129–36 (2009).
4. Bonner-Weir, S., Sullivan, B. A. & Weir, G. C. Human Islet Morphology Revisited: Human and Rodent Islets Are Not So Different After All. *J Histochem Cytochem* **63**, 604–12 (2015).
5. Bosco, D. *et al.* Unique arrangement of alpha- and beta-cells in human islets of Langerhans. *Diabetes* **59**, 1202–10 (2010).

6. Eberhard, D. & Lammert, E. The pancreatic beta-cell in the islet and organ community. *Curr Opin Genet Dev* **19**, 469–75 (2009).
7. Arrojo e Drigo, R. *et al.* New insights into the architecture of the islet of Langerhans: a focused cross-species assessment. *Diabetologia* **58**, 2218–28 (2015).
8. Mezza, T. & Kulkarni, R. N. The regulation of pre- and post-maturational plasticity of mammalian islet cell mass. *Diabetologia* **57**, 1291–303 (2014).
9. Tokuyama, Y. *et al.* Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. *Diabetes* **44**, 1447–57 (1995).
10. Baetens, D. *et al.* Alteration of islet cell populations in spontaneously diabetic mice. *Diabetes* **27**, 1–7 (1978).
11. Gomez Dumm, C. L., Semino, M. C. & Gagliardino, J. J. Sequential morphological changes in pancreatic islets of spontaneously diabetic rats. *Pancreas* **5**, 533–9 (1990).
12. Starich, G. H., Zafirova, M., Jablenska, R., Petkov, P. & Lardinois, C. K. A morphological and immunohistochemical investigation of endocrine pancreata from obese ob+/ob+ mice. *Acta Histochem* **90**, 93–101 (1991).
13. Kilimnik, G. *et al.* Altered islet composition and disproportionate loss of large islets in patients with type 2 diabetes. *PLoS One* **6**, e27445 (2011).
14. Ogneva, V. & Nikolov, B. Changes in pancreatic islets in aging Wistar and Zucker rats: a histochemical and ultrastructural morphometric study. *Mech Ageing Dev* **74**, 35–46 (1994).
15. Lavallard, V. *et al.* Cell rearrangement in transplanted human islets. *FASEB J* **30**, 748–60 (2016).
16. Morini, S. *et al.* Revascularization and remodelling of pancreatic islets grafted under the kidney capsule. *J Anat* **210**, 565–77 (2007).
17. Morini, S. *et al.* Morphological changes of isolated rat pancreatic islets: a structural, ultrastructural and morphometric study. *J Anat* **209**, 381–92 (2006).
18. Henriksnas, J. *et al.* Markedly decreased blood perfusion of pancreatic islets transplanted intraportally into the liver: disruption of islet integrity necessary for islet revascularization. *Diabetes* **61**, 665–73 (2012).
19. Blum, B. *et al.* Functional beta-cell maturation is marked by an increased glucose threshold and by expression of urocortin 3. *Nat Biotechnol* **30**, 261–4 (2012).
20. Pagliuca, F. W. *et al.* Generation of functional human pancreatic beta cells *in vitro*. *Cell* **159**, 428–39 (2014).
21. Pan, F. C. & Wright, C. Pancreas organogenesis: from bud to plexus to gland. *Dev Dyn* **240**, 530–65 (2011).
22. Bastidas-Ponce, A., Scheibner, K., Lickert, H. & Bakhti, M. Cellular and molecular mechanisms coordinating pancreas development. *Development* **144**, 2873–2888 (2017).
23. Halban, P. A., Powers, S. L., George, K. L. & Bonner-Weir, S. Spontaneous reassociation of dispersed adult rat pancreatic islet cells into aggregates with three-dimensional architecture typical of native islets. *Diabetes* **36**, 783–90 (1987).
24. Orci, L. & Unger, R. H. Functional subdivision of islets of Langerhans and possible role of D cells. *Lancet* **2**, 1243–4 (1975).
25. Erlandsen, S. L., Hegre, O. D., Parsons, J. A., McEvoy, R. C. & Elde, R. P. Pancreatic islet cell hormones distribution of cell types in the islet and evidence for the presence of somatostatin and gastrin within the D cell. *J Histochem Cytochem* **24**, 883–97 (1976).
26. Shih, H. P., Wang, A. & Sander, M. Pancreas organogenesis: from lineage determination to morphogenesis. *Annu Rev Cell Dev Biol* **29**, 81–105 (2013).
27. Blockus, H. & Chedotal, A. Slit-Robo signaling. *Development* **143**, 3037–44 (2016).
28. Xin, Y. *et al.* RNA Sequencing of Single Human Islet Cells Reveals Type 2 Diabetes Genes. *Cell Metab* **24**, 608–615 (2016).
29. Fadista, J. *et al.* Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. *Proc Natl Acad Sci USA* **111**, 13924–9 (2014).
30. Segerstolpe, A. *et al.* Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes. *Cell Metab* **24**, 593–607 (2016).
31. Wang, Y. J. *et al.* Single-Cell Transcriptomics of the Human Endocrine Pancreas. *Diabetes* **65**, 3028–38 (2016).
32. Qiu, W. L. *et al.* Deciphering Pancreatic Islet beta Cell and alpha Cell Maturation Pathways and Characteristic Features at the Single-Cell Level. *Cell Metab* **25**, 1194–1205 e4 (2017).
33. Yang, Y. H., Manning Fox, J. E., Zhang, K. L., MacDonald, P. E. & Johnson, J. D. Intra-islet SLIT-ROBO signaling is required for beta-cell survival and potentiates insulin secretion. *Proc Natl Acad Sci USA* **110**, 16480–5 (2013).
34. Branchfield, K. *et al.* Pulmonary neuroendocrine cells function as airway sensors to control lung immune response. *Science* **351**, 707–10 (2016).
35. Pauerstein, P. T. *et al.* A radial axis defined by semaphorin-to-neuropilin signaling controls pancreatic islet morphogenesis. *Development* **144**, 3744–3754 (2017).
36. Konstantinova, I. *et al.* EphA-Ephrin-A-mediated beta cell communication regulates insulin secretion from pancreatic islets. *Cell* **129**, 359–70 (2007).
37. Villaseñor, A. *et al.* EphB3 marks delaminating endocrine progenitor cells in the developing pancreas. *Dev Dyn* **241**, 1008–19 (2012).
38. Esni, F. *et al.* Neural cell adhesion molecule (N-CAM) is required for cell type segregation and normal ultrastructure in pancreatic islets. *J Cell Biol* **144**, 325–37 (1999).
39. Cirulli, V. *et al.* Expression of neural cell adhesion molecule (N-CAM) in rat islets and its role in islet cell type segregation. *J Cell Sci* **107**(Pt 6), 1429–36 (1994).
40. Rouiller, D. G., Cirulli, V. & Halban, P. A. Differences in aggregation properties and levels of the neural cell adhesion molecule (NCAM) between islet cell types. *Exp Cell Res* **191**, 305–12 (1990).
41. Borden, P., Houtz, J., Leach, S. D. & Kuruvilla, R. Sympathetic innervation during development is necessary for pancreatic islet architecture and functional maturation. *Cell Rep* **4**, 287–301 (2013).
42. Domyan, E. T. *et al.* Roundabout receptors are critical for foregut separation from the body wall. *Dev Cell* **24**, 52–63 (2013).
43. Friedl, P. & Mayor, R. Tuning Collective Cell Migration by Cell-Cell Junction Regulation. *Cold Spring Harb Perspect Biol* **9** (2017).
44. Gouzi, M., Kim, Y. H., Katsumoto, K., Johansson, K. & Grapin-Botton, A. Neurogenin3 initiates stepwise delamination of differentiating endocrine cells during pancreas development. *Dev Dyn* **240**, 589–604 (2011).
45. Miller, K. *et al.* Islet formation during the neonatal development in mice. *PLoS One* **4**, e7739 (2009).
46. Schonhoff, S. E., Giel-Moloney, M. & Leiter, A. B. Neurogenin 3-expressing progenitor cells in the gastrointestinal tract differentiate into both endocrine and non-endocrine cell types. *Dev Biol* **270**, 443–54 (2004).
47. Gu, G., Dubauskaite, J. & Melton, D. A. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. *Development* **129**, 2447–57 (2002).
48. Gradwohl, G., Dierich, A., LeMeur, M. & Guillemot, F. neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. *Proc Natl Acad Sci USA* **97**, 1607–11 (2000).
49. Rama, N. *et al.* Slit2 signaling through Robo1 and Robo2 is required for retinal neovascularization. *Nat Med* **21**, 483–91 (2015).
50. Postic, C. *et al.* Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. *J Biol Chem* **274**, 305–15 (1999).
51. Keller, M. P. *et al.* A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. *Genome Res* **18**, 706–16 (2008).
52. van der Meulen, T. *et al.* Virgin Beta Cells Persist throughout Life at a Neogenic Niche within Pancreatic Islets. *Cell Metab* **25**, 911–926 e6 (2017).
53. van der Meulen, T. *et al.* Urocortin 3 marks mature human primary and embryonic stem cell-derived pancreatic alpha and beta cells. *PLoS One* **7**, e2181 (2012).

54. Gannon, M. *et al.* Persistent expression of HNF6 in islet endocrine cells causes disrupted islet architecture and loss of beta cell function. *Development* **127**, 2883–95 (2000).
55. Sinagoga, K. L. *et al.* Distinct roles for the mTOR pathway in postnatal morphogenesis, maturation and function of pancreatic islets. *Development* **144**, 2402–2414 (2017).
56. Wilding Crawford, L. *et al.* Gene expression profiling of a mouse model of pancreatic islet dysmorphogenesis. *PLoS One* **3**, e1611 (2008).
57. Doyle, M. J. & Sussel, L. Nkx2.2 regulates beta-cell function in the mature islet. *Diabetes* **56**, 1999–2007 (2007).
58. Yamagata, K. *et al.* Overexpression of dominant-negative mutant hepatocyte nuclear factor-1 alpha in pancreatic beta-cells causes abnormal islet architecture with decreased expression of E-cadherin, reduced beta-cell proliferation, and diabetes. *Diabetes* **51**, 114–23 (2002).
59. Jimenez-Caliani, A. J. *et al.* alphaE-Catenin Is a Positive Regulator of Pancreatic Islet Cell Lineage Differentiation. *Cell Rep* **20**, 1295–1306 (2017).
60. Gu, C. *et al.* Pancreatic beta cells require NeuroD to achieve and maintain functional maturity. *Cell Metab* **11**, 298–310 (2010).
61. Bastidas-Ponce, A. *et al.* Foxa2 and Pdx1 cooperatively regulate postnatal maturation of pancreatic beta-cells. *Mol Metab* **6**, 524–534 (2017).
62. Blum, B. *et al.* Reversal of beta cell de-differentiation by a small molecule inhibitor of the TGFbeta pathway. *Elife* **3**, e02809 (2014).
63. Shiota, C. *et al.* alpha-Cells are dispensable in postnatal morphogenesis and maturation of mouse pancreatic islets. *Am J Physiol Endocrinol Metab* **305**, E1030–40 (2013).
64. Gong, S. *et al.* A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. *Nature* **425**, 917–25 (2003).
65. Magnuson, M. A. & Osipovich, A. B. Pancreas-specific Cre driver lines and considerations for their prudent use. *Cell Metab* **18**, 9–20 (2013).
66. Song, J., Xu, Y., Hu, X., Choi, B. & Tong, Q. Brain expression of Cre recombinase driven by pancreas-specific promoters. *Genesis* **48**, 628–34 (2010).
67. Georgia, S. & Bhushan, A. Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. *J Clin Invest* **114**, 963–8 (2004).
68. Stolovich-Rain, M. *et al.* Weaning triggers a maturation step of pancreatic beta cells. *Dev Cell* **32**, 535–45 (2015).

## Acknowledgements

We thank Xin Sun (UCSD) for mice and advice. We thank Le Ma (Thomas Jefferson University) for mice. We are grateful to Sutichot Dex Nimkulrat for technical assistance and to members of the Blum lab, especially Emily Cade, for valuable discussions. We are also grateful to Nadav Sharon, Yoav Mayshar and Grace Boekhoff-Falk for critically reading the manuscript and to Barbara Lewis for English editing. This work was funded in part by the DRC at Washington University, Grant No. 2 P30 DK020579, as well as a Pilot Award No. UL1TR000427 from the UW-Madison Institute for Clinical and Translational Research (ICTR) and the UW-Madison Stem Cell & Regenerative Medicine Center.

## Author Contributions

B.B. and M.T.A. conceived and designed the experiments. M.T.A., J.M.G., J.H.P. and F.M.B. performed experiments and analyzed data. B.B., M.T.A. and J.M.G. wrote the manuscript. All authors discussed the results and commented on the manuscript.

## Additional Information

**Supplementary information** accompanies this paper at <https://doi.org/10.1038/s41598-018-29118-x>.

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018